^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CRKL (CRK Like Proto-Oncogene, Adaptor Protein)

    i
    Other names: CRKL, CRK Like Proto-Oncogene, Adaptor Protein, V-Crk Avian Sarcoma Virus CT10 Oncogene Homolog-Like, Crk-Like Protein
    14d
    Proteomic insights into Helicobacter pylori infection in stomach cells, revealing host response and host-targeted therapeutics repurposing. (PubMed, Expert Rev Proteomics)
    Clinically approved drugs such as Dasatinib (targeting CSK) and Crizotinib (targeting MET) emerged as promising candidates due to favorable pharmacokinetics and known bioactivity. Host-directed therapeutics could offer alternative strategies to conventional antibiotic therapy, addressing challenges such as resistance and infection recurrence, providing a foundation for future experimental validation and development of host-targeted interventions for infection control.
    Journal
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • MARK2 (Microtubule Affinity Regulating Kinase 2) • RELA (RELA Proto-Oncogene)
    |
    Xalkori (crizotinib) • dasatinib
    21d
    ETS Variant Transcription Factor 6 Promotes Glucose Metabolism Reprogramming in HCC. (PubMed, J Cell Mol Med)
    Mechanistically, ETV6 binds to the miR-429 promoter, mediating glucose metabolic reprogramming in HCC cells by targeting CRKL via the PI3K/AKT pathway. Taken together, these findings reveal that the ETV6-miR-429-CRKL regulatory circuitry plays a crucial role in glucose metabolic reprogramming in HCC, offering novel insight and a potential target for cancer therapy.
    Journal
    |
    ETV6 (ETS Variant Transcription Factor 6) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • MIR429 (MicroRNA 429) • TFAM (Transcription Factor A, Mitochondrial)
    27d
    Conversational AI-Enabled Precision Oncology Reveals Context-Dependent MAPK Pathway Alterations in Hispanic/Latino and Non-Hispanic White Colorectal Cancer Stratified by Age and FOLFOX Exposure. (PubMed, Cancers (Basel))
    Although MAPK alterations are pervasive in CRC, their distribution varies meaningfully by ancestry, age, and treatment exposure. These findings highlight NF1, MAPK3, RPS6KA4, and PDGFRB as potential biomarkers in EOCRC and H/L patients, supporting the need for ancestry-aware precision oncology approaches.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NF1 (Neurofibromin 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FGF4 (Fibroblast growth factor 4) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • MAPK1 (Mitogen-activated protein kinase 1) • DUSP4 (Dual Specificity Phosphatase 4) • MAPK3 (Mitogen-Activated Protein Kinase 3) • RPS6KA6 (Ribosomal Protein S6 Kinase A6)
    |
    5-fluorouracil • leucovorin calcium
    2ms
    Asciminib With or Without Sildenafil for Brain Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jun 2027 --> Aug 2027
    Trial completion date
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Scemblix (asciminib) • sildenafil
    3ms
    Genomic and Demographic Characteristics of Angiosarcoma as Described in the AACR Project GENIE Registry. (PubMed, Cancers (Basel))
    In one of the largest genomic analyses of angiosarcoma to date, we identified recurrent alterations, suggesting potential future therapeutic targets.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • KDR (Kinase insert domain receptor) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler) • NOTCH2 (Notch 2) • FAT1 (FAT atypical cadherin 1) • FLT4 (Fms-related tyrosine kinase 4) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • POT1 (Protection of telomeres 1) • MSI2 (Musashi RNA Binding Protein 2) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    TP53 mutation • PIK3CA mutation • CDKN2A deletion
    6ms
    Targeting melanoma resistance: Novel oxindole and non-oxindole-based benzimidazole derivatives as potent dual inhibitors of BRAFV600E and ABL2 kinases. (PubMed, Eur J Med Chem)
    Cytotoxicity assays in resistant melanoma cells showed IC50 values of 12.3 μM (A375) and 20.1 μM (A375-R), demonstrating potency comparable to vemurafenib...Furthermore, the apoptotic efficacy of 8h demonstrated a significant increase in the percentage of late apoptotic cells, reaching 13.89 % in treated cells, in contrast to 0.15 % in untreated cells. In Silico ADME profiling indicated that the proposed compounds are suitable drug candidates.
    Journal
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib)
    6ms
    Modelling Acral Melanoma in Admixed Brazilians Uncovers Genomic Drivers and Targetable Pathways. (PubMed, medRxiv)
    Notably, the pan-RAS(ON) inhibitor RMC-7977 effectively reduced viability in NRAS -, KRAS -, and KIT -mutant AM cell lines. Finally, CRISPR screens revealed dependencies selectively essential in AM, including CRKL and SF3B4 , highlighting previously unrecognized vulnerabilities. Our findings emphasize the distinct biology of AM compared to other subtypes of melanoma, provide a valuable resource of models reflective of Latin American ancestry, and identify potential drivers and therapeutic targets.
    Journal • Tumor mutational burden
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ATM (ATM serine/threonine kinase) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CHEK1 (Checkpoint kinase 1) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein)
    |
    KRAS mutation • TMB-L
    |
    RMC-7977
    8ms
    Asciminib With or Without Sildenafil for Brain Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine
    New P1 trial
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Scemblix (asciminib) • sildenafil
    10ms
    The p130Cas-Crk/CrkL Axis: A Therapeutic Target for Invasive Cancers Unveiled by Collaboration Among p130Cas, Crk, and CrkL. (PubMed, Int J Mol Sci)
    Understanding the tumor cell migration and invasion that require both p130Cas and Crk/CrkL is necessary to further evaluate the role of the p130Cas-Crk/CrkL axis in cancer. Establishing the contribution of the p130Cas-Crk/CrkL axis to cancer will facilitate the development of cancer drugs targeting the axis to inhibit cancer cell dissemination and improve patient outcomes.
    Review • Journal
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein)
    12ms
    CRKL silencing inhibits melanoma growth and enhances its chemotherapy sensitivity through the PI3K/AKT and NLRP3/GSDMD pathways. (PubMed, Biochem Pharmacol)
    Importantly, our study demonstrated that interfering with CRKL expression enhanced the chemotherapy sensitivity of melanoma cells to cisplatin by regulating PI3K/AKT and NLRP3/GSDMD signaling pathways. In conclusion, our study uncovers a novel molecular mechanism by which CRKL functions in melanoma and highlights potential therapeutic strategies for improving chemotherapy sensitivity in melanoma patients.
    Journal
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • MMP9 (Matrix metallopeptidase 9) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    cisplatin
    1year
    The integrative genomic and functional immunological analyses of colorectal cancer initiating cells to modulate stemness properties and the susceptibility to immune responses. (PubMed, J Transl Med)
    Our study demonstrates that the modulation of miRNA-15a in CICs not only suppresses the tumorigenic properties but also enhances their visibility to the immune system by upregulating antigen presentation and reducing immunomodulatory molecules. These findings suggest that combining miRNA modulation with epigenetic or immunomodulatory agents holds significant promise for overcoming treatment resistance in CRC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • SOX2 • TGFB1 (Transforming Growth Factor Beta 1) • IL4 (Interleukin 4) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit) • SMAD3 (SMAD Family Member 3)